Regulatory Approval - Replimune shares surged following US regulators' acceptance of its resubmitted application for a skin cancer treatment [1] - The acceptance suggests a potential reversal of a previous denial [1] Company Focus - Replimune is developing a treatment for skin cancer [1]

Regulatory Action - US regulators rejected Replimune's skin cancer treatment [1] - The rejection signals a potentially stricter stance on drug approvals by the agency's new leadership [1] Company Impact - Replimune experienced a setback with the rejection of its skin cancer treatment [1]

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive focuses on sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Group 2 - Proactive is a forward-looking company that adopts technology enthusiastically, utilizing decades of expertise and experience [4] - The company employs automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]